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A b s t r a c t  
The objective of this work was to formulate and evaluate a controlled-release Oxypentifylline 
microspheres that fulfill the requirements for extended release medications using Ammonio 
Methacrylate Copolymer RS100 as polymeric material. The microsphere were prepared by quasi-
emulsion solvent diffusion technique. The effect of process variables such as drug to polymer ratio, 
stirring rate, and concentration of emulsifier on mean particle size, yield, entrapment efficiency and 
in vitro release characteristics of microspheres were studied. The prepared microspheres were 
spherical in shape. The size range varied  from  325.45  to  518.54  µm. The microspheres showed 
high entrapment efficiency (94.22%) and the release was extended up to 24 hrs. The best 
microsphere formulation was selected and subjected for in vivo studies which reveal that the 
bioavailability of the drug increased by more than 3.4 times by formulating it into microspheres. 
This study  indicated  that  Ammonio Methacrylate Copolymer RS 100 can use successfully to 
sustain the release of Oxypentifylline 




Oxypentifylline [OXP] was the first drug approved for the 
treatment of intermittent secondary to chronic occlusive vascular 
disease and Reynaud’s syndromes [1]. In addition, it significantly 
increases red cells deformability in patients with chronic occlusive 
arterial disease, diabetic arteriopathies, cerebrovascular disorders 
and retinal vascular disorders [2,3]. [OXP] is a white, crystalline or 
microcrystalline powder, which has a bitter taste and only a slight 
characteristic odor [4,5], it  is readily absorbed [at levels 
exceeding 95%] from the gastrointestinal tract, but undergoes 
extensive first-pass hepatic metabolism [60–70%] [6]. with  t1/2 of 
1.63 ± 0.8 hours. [7].About 89% of orally administered [OXP] was 
excreted in the urine after six hours [8]. Due to short half-live it 
require frequent dosing which lead to fluctuation in blood levels, 
and decrease patient compliance. These attributes make [OXP]  a 
good candidate for controlled release dosage form. 
 Microspheres are one of the multiparticulate drug delivery 
systems [9], play a vital role in the development of 
controlled/sustained release drug delivery systems [10]. 
Microspheres can be defined as solid, approximately spherical 
particles ranging from 1 to 1000μm, containing dispersed drug in 





Several methods, including Emulsion solvent evaporation 
technique [12], phase-separation or coacervation method [ 13],  
emulsification diffusion method [14],  and spray drying method 
[15] are commonly used for the preparation of microspheres.  
Several publications have described drug-containing 
microspheres using the Ammonio Methacrylate Copolymer as the 
encapsulating materials. They are a family of polymers based on 
acrylic and methacrylic acids suitable for use in orally 
administered drug delivery systems. They have been used in the 
microencapsulation of drugs [16]. Some dissolve rapidly at clearly 
defined pH values, whereas two grades;RL and RS, are insoluble 
in aqueous media water and digestive juices, but swell and are 
permeable, which means that the drugs can be released by 
diffusion [17]. Therefore, the permeability of drug through 
Ammonio Methacrylate Copolymer RS and/or RL is independent 
of the pH of the digestive tract [18].  
Ammonio Methacrylate Copolymer RS100 [AMRS-Polymer] is a 
water-insoluble polymer that is widely used as a wall material for 
sustained release microspheres due to its biocompatibility, good 
stability, easy fabrication and low cost.  
The main objective of this work was to investigate the possibility 
of obtaining a sustained release formulation of [OXP] 
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[AMRS-Polymer] in various drug: polymer ratios. Investigation of 
the effect of various processing and formulation factors such as 
drug to polymer ratio, stirring speed, surfactant concentration and 
others on the shape, mean particle size, yield of production, 
particle size distribution, encapsulation efficiency, and in-vitro 
release rate of drug from the microspheres were performed 
 
Material and Methods 
Materials 
[OXP] [kindly supplied by ALKAN pharma company, 6th October 
City, Cairo, Egypt], Ammonio Methacrylate Copolymer RS100 
[Rhom Pharma, GMBH, Dermstadt, Germany],  Dichloromethane, 
ethanol, and sodium lauryl sulphate [Sigma, St.Louis, MO, U.S.A], 
polyvinyl alcohol [Merck, Germany]. All other chemicals were of 
analytical grade and distilled water was used for all experiments. 
 
Preparation of [OXP]-loaded microspheres 
In order to prepare the microspheres, modified quasi-emulsion 
solvent diffusion method which was adapted from the process 
described by [19-22]. Briefly, weighed amount of [OXP]  and . 
[AMRS-Polymer]polymer were dissolved in ethanol at 45OC..The 
formed ethanolic solution was poured into water containing 
polyvinyl alcohol and was stirring continuously for 3-4 hrs until all 
solvent was evaporated. The system was thermally controlled at 
20OC, the microspheres were separated by filtration, washed 
twice with 50 mL of water and then dried in oven at 37OC for 24 h. 
Dried microspheres were stored in a desiccators containing 
CaCl2.  
The preparation of microsphere involves various process 
variables, include 
Effect of polymer concentration [[AMRS-Polymer]were used in 
ratios 1:1, 1:2, 1:3, 1:4 and 1:5 to obtain significant different 
characteristics] 
Effect of stirring rate [400, 800, and 1200 rpm] 
Effect of surfactant concentration [ 0.1%, 0.3%, and 0.6%] 
Formulations with different variables were prepared as shown in 
table [1].  
 
Fourier Transformed Infrared [FT-IR] Spectroscopy 
The sample powder was dispersed in KBr powder and analyzed 
after converting into pallet. FT-IR spectra were obtained by 
powder diffused reflectance on a FT-Infrared spectrophotometer. 
 
Differential Scanning Calorimetry [DSC] 
DSC curves were recorded on a scanning calorimeter equipped 
with a thermal analysis data system [Shimadzu, Differential 
Scanning Calorimeter [Tokyo, Japan]. Pure drug, microspheres, 




The relative yield was calculated based on the amount of 
microspheres of each formulation obtained relative to the amount 




    Weight of microspheres 
%Yield  =                                                               X 100 
      Weight of drug + Weight of polymer 
 
Particle size analysis 
Simple optical microscope was used for particle size 
measurement of individual microsphere. Optical micrometer was 
calibrated using standard stage micrometer. According to 
microscopic method of particle size analysis, slides of various 
batches of microspheres were prepared using dilute suspension 
of microspheres in liquid paraffin. Particle size of 100 numbers of 
microspheres from each batch was measured for calculating size 
distribution and average particle size. Results were reported as 
means ± S.D. The mean particle size of microspheres was 
calculated using the following formula [24,25].  
 
Mean Particle size =Σ [Mean particle size of the fraction X weight fraction] 
                                                    Weight fraction 
 
Entrapment efficiency 
To evaluate the amount of the drug inside the microspheres, an 
indirect method was used [26]. Aliquots from the filtered solutions 
remaining after removal of the microspheres were assayed 
spectrophotometrically at 274 nm. The amount of drug entrapped 
was calculated from the difference between the total amount of 
drug added and the amount of drug found in the filtered solution. 
About 100 mg of microspheres were completely dissolved in 500 
ml of phosphate buffer solutions [pH 7.4], and stirred for 1h. Then, 
2 ml of solution was filtered and the concentration of drug was 
determined spectrophotometrically by UV at 274 nm. 
Efficiency of drug entrapment was calculated in terms of 
percentage drug entrapment [%EE] as per the following formula: 
 
%EE = [Practical drug loading/Theoretical drug loading] ×100 
 
In-vitro dissolution studies of OXP-loaded 
microspheres 
Drug dissolution test of microspheres was performed by USP II 
paddle type apparatus. Microspheres equivalent to 400 mg of 
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drug were added to 400ml dissolution media. The content was 
rotated at 100 rpm at 37°C ± 0.5°C. The pH of dissolution media 
were kept 1.2 for 2 hr using 0.1N HCl, then 480ml of phosphate 
buffer and 20ml of 2M NaOH added to adjust the pH to 7.2 and 
maintained up to 24 hr. 5ml of each samples were withdrawn from 
the dissolution medium at various time intervals and replaced by 
an equal volume of dissolution medium [27].. After filtration and 
suitable dilution, the samples were analyzed 
spectrophotometrically at 274 nm. The concentration of [OXP] in 
sample was calculated based on calibration curves taken in both 
the acidic 0.1NHCl media [n=3, R2 = 0.999], and basic media 
[n=3, R2 = 0.999].[27] 
Morphology of microspheres 
The shape and surface characteristics of microspheres were 
analyzed by scanning electron microscopy [SEM]. Sample was 
dusted on a double sided adhesive tape applied previously to an 
aluminium stub. Excess sample was removed and stub coated 
[Polaron Sputter 7040] with 30 nm layer of gold palladium 
observed with a scanning electron microscope [27]. 
. 
In-vivo evaluation of microspheres 
Chromatographic conditions:  
The mobile phase was a mixture of acetonitrile: water [40: 60], 
adjusted to pH 3 with glacial acetic acid. The mixture was filtered 
by passing it through a 0.45 um membrane filter and degassed by 
mean of vacuum pump. The mobile phase was delivered into the 
HPLC apparatus at a flow rate of 1 ml/min, the detection was 
conducted at 274 nm. 
 
Preparation of in-vitro Standard calibration curve 
1. Stock and Working Standard Solutions: The standard 
solution was prepared by dissolving 100 mg [OXP] in 
100 ml mobile phase. The working standard solution 
was prepared by taking 10 ml of the above solution in 
100 ml volumetric flask and completed to the volume 
with mobile phase [100 ug/ml].  
2. Stock and Working Internal Standard Solution: The 
internal standard solution was prepared by dissolving 
100 mg of ciprofloxacin HCl in 100 ml volumetric flask 
and completed to the volume with the mobile phase. 
The working internal standard was prepared by taking 
10 ml of the above solution in 100 ml volumetric flask 
and completed to the volume with mobile phase [100 
ug/ml].  
 
Calibration Curve:  
Standard samples were prepared to provide final concentrations 
of [OXP] ranging from 10 to 70 ug/ml, by transferring 0.5 ml of 
working internal standard solution and aliquots of [OXP] working 
standard 
 
Bioavailability study of [OXP] in experimental animals: 
Male albino rabbits [weighing 1.5-2 kg] were used for the 
bioavailability study. Animals were divided into three groups of 
three rabbits in each group. Twelve hours before drug 
administration, food was withdrawn until 24 hrs post-dosing, and 
the rabbits had free access to water throughout the experiment. 
The study was designed as a single oral dose. All groups received 
an equivalent of 10 mg [OXP] / kg body weight of rabbits [28]. 
Group 1 received [OXP] alone, group 2 received [OXP] 
commercial preparation [Trental® SR 400 mg], group 3 received 
formula F8 [the best microspheres formulation that exhibited high 
EE% and the optimum release rate]. One hard gelatin capsule 
was administered to each rabbit through a stomach tube with the 
aid of distilled water.. Blood samples [about 1ml] were withdrawn 
from the sinus orbital into heparinized tubes at 0, 0.5, 1, 2, 3, 4, 6, 
8, and 24 hours after each administration.   The blood samples 
were centrifuged immediately at 3000 rpm for 10 min to obtain the 
plasma samples and were stored at -200C for subsequent assay. 
Robert et al [29]. developed a HPLC method for determination of 
[OXP] and its metabolites in human serum, the method required 
extraction of the analytes with a mixture of 5% isopropanol in 
chloroform,   after addition of 0.1 N HCl or NaOH .The detection 
was effected using the UV absorbance at 273 nm, and the 
detection limit was found to be 5 ng/ml 
     Pharmacokinetics parameters were calculated from the plasma 
level data obtained for the individual rabbit per each group and 
presented as mean ± S.D. [Cmax, µg/ml],  [Tmax, hr], [AUC 0-24, µg 
ml-1 h], [AUC 0-∞], and relative bioavailability were calculated  
Statistical analysis 
All results are represented as mean ± S.D. One way analysis of 
variance [ANOVA] was employed to assess the significance of the 
difference between the tested microsphere formulations and the 
control at a level [p≤ 0.05] using SPSS  program [30]. 
Results and discussion 
Particle size analysis of [OXP] loaded microspheres 
Results showed that particle size of prepared microspheres was 
in the range of 325.45±6.65  to  518.54±10.03  µm as shown in 
table [1]. The data obtained showed that, at a low concentration of 
polymer [1:1 ratio] no microsphere product was obtained[formula 
F1, F4, and F5]. the mean diameter was increased significantly 
[P=0.001] as the drug: polymer ratio varied from 1:2 to 1:5. Low 
concentration of AMRS-Polymer resulted in a low viscosity of the 
polymer solution which in turn resulted in smaller emulsion 
droplets in the aqueous phase [31,32]. It was observed that as the 
stirring rate was 400 rpm [formulae  F1, F2, F3], there was no 
formation of spherical microspheres and mass crops were 
obtained. This could be due inadequate agitation to disperse the 
inner phase in the total mass. Therefore, particles were found to 
settle at the bottom of vessel .At stirring speeds of 800, 1200 rpm, 
the resulting high turbulence caused frothing and adhesion to the 
container wall and paddle Therefore, the mean particle size of 
microshperes decreased. Similar results were reported by [33] 
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Increasing the concentration of surfactant from 0.1 % to 0.6 % 
resulted in a significant decrease [P<0.05] in the mean diameter 
of microspheres. This can attributed to that the lower 
concentration of emulsifier may not be sufficient to cover the 
droplets of emulsion  resulting in coalescence of emulsion 
droplets and lead to aggregation and fusion of the formed droplets 
resulting in increasing microspheres particle size [34] 
Percentage yield of microspheres 
The data revealed that, The % yield of different microspheres 
varied from [70.89±2.04 to 93.13±2.87], as shown in table [1]. The 
data obtained showed that, the percentage yield was decreased 
at a low concentration of polymer [1:2 ratio]; at higher stirring rate 
[1200 rpm]; and at high surfactant concentration [0.6%] This 
reduction in the percentage yield in these cases may be due to; a- 
the small size of microsphere obtained in all these cases which 
may loss during filtration and washing processes, b- increasing 
surfactant concentration results in a brittle surface of 
microspheres, which lead to a drug loss during washing of 
microspheres[35,36]. 
The maximum percentage yield obtain in formulae F8, F9 which 
contain higher ratio of drug:polymer [1:4, 1:5] and prepared at 
intermediate stirring rate [800 rpm], with intermediate surfactant 
concentration [0.3%]. 
Analysis of entrapment efficiency 
The results indicate that the EE% increased significantly [P<0.05] 
as the drug: polymer ratio varied from 1:1 to 1:5 as shown in table 
[1], which can be explained by increased viscosity of the organic 
phase and dense internal structure, therefore less drug loss 
during evaporation [37,38]. The results indicate that there was a 
significant decrease [P> 0.05] in the EE% with increasing the 
stirring rate for preparation of microspheres. The encapsulation 
increased with decreasing the stirring rate. A probably explanation 
is that, the surface area of large particles is lower which lead to 
less transport of the drug into the external aqueous phase [31], 
formulae F8, F9 also showed higher %EE 
 
In-vitro release studies of OXP loaded microspheres 
The results indicate that the dissolution of the pure drug was 
faster in comparison to that released from any microsphere 
formulation. 
The release from microspheres was greatly extended and delayed 
by increase polymer concentration [figure 1, 2], this may be due 
to; a-increase in the wall thickness of the microspheres arising 
due to the increase in polymer conc. leading to increase the 
length of diffusional pathway through the polymer membrane [39], 
b- increase polymer conc. Lead to decrease amount of drug close 
to surface [27], c- as the conc. Of polymer increase, large amount 
of drug got bind in the polymer matrix as a result the rate of 
release decrease.[26] 
At low polymer conc.[drug:polymer ratio 1:2], more than 35% 
released during first hour [ formulae F6,10,14,18] which was not 
satisfactory to the desired criteria for sustained release. By 
increase polymer conc. [ drug: polymer ratio 1:3, 1:4], 25% and 
20% were released in first hour respectively, which fulfilled the 
desired criteria. At high polymer conc. [drug: polymer ratio 1:5] 
less than 9% released in first hour [ formulae F9,13,17 and 21] 
which was not satisfactory to the desired criteria. 
The results also indicate that, increasing the stirring rate resulted 
in increase in the rate of drug release. These may be due to; a- 
that smaller particle size microspheres are produced at higher 
stirring rates, which possess a large surface area leading to 
higher release rate. B- microsphere prepared at higher stirring 
rate are more porous, exhibit fast release of drug [27,40], 
formulae F19, F20 release more than 90% in 7 hours, which was 
not acceptable to the desired criteria for sustained release.  
The rate and amount of drug release is increased as the 
concentration of the surfactant is increased at constant drug: 
polymer ratio as shown in figure [3]. This is due to the increase in 
wettability and better solvent penetration as the surfactant is 
increased. [41].  
Formulae F8 fulfilled all the desired criteria required in sustained 
release product [ 20% released in first hour, t50% dissolution was 
7 hr, and t85% dissolution was 20hr] 
 The release mechanism of OXP from formulation was determined 
by comparing their respective correlation co-efficient. It would 
appear that the mechanism of release from microspheres was 
diffusion-controlled. 
When the release rate constants of microspheres were compared, 
it was found to follow the Higuchi model. According to this model, 
the drug releases from these formulations may be controlled by 
diffusion through the micropores 
In-vivo evaluation of microspheres 
Bioavailability of [OXP] after oral administration 
The mean pharmacokinetic parameters of [OXP] from different 
formulations represented by the value of Cmax, Tmax, Kel, t1/2, 
AUC0-24 and AUC0-α are represented in table [2].And the mean 
plasma concentrations as a function of time for [OXP] were 
illustrated in figure [3]. From the obtained results, there was a 
noticeable difference in the Tmax between the pure drug and the 
tested formulations, it was observed that, the absorption of plain 
[OXP] was rapid and reached its peak plasma concentration in 
[1.23±0.09 h], whereas, the mean Tmax for the commercial trental 
SR tablet and the tested formulation [F8] were 5.32±0.51 and 
7.79±0.24 h, respectively. [Cmax] were 25.43±2.54ng/ml for trental 
tablet, 22.54±1.43 ng/ml for formula [F8] compared to 37.43±2.97 
ng/ml for plain [OXP]. The increase in the mean Tmax and the 
decrease in the mean Cmax compared to the plain drug indicated 
the controlled release effect of the microsphere formulations.  
The mean AUC 0-24 was found to be 2340.65±10.43ng.h.ml-1 for 
formula [F8] compared to 660.87±8.64 ng.h.ml-1 for plain OXP, 
and 1420.54±8.65 ng.h.ml-1 for trental tablet. These results 
confirmed the prolonged release of the tested formulation.  
From the obtained data, it was found that, the relative 
bioavailability of [OXP] from formul F8 was 340% compared to 
control [plain drug] and 164% compared to commercial available 
trental tablet. One of the main reasons for such a big difference 
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between sustained-release [OXP] microspheres and [OXP] is that 
the absolute bioavailability of [OXP] was extremely low because 
of the poor solubility of the drug [42], and extensive first-pass 
hepatic metabolism [60–70%] [80]. with  t1/2 of 1.63 ± 0.8 hours. 
[6].About 89% of orally administered [OXP] was excreted in the 
urine after six hours [8]. Also, the increase in the relative 
bioavailability may be due to the slow release of the drug from the 
microspheres which led to a longer absorption and distribution 
period for the drug loaded microspheres than that of the free form 
which increase the half life of drug from 1.6 hr to about 6.1hr.  
References 
Conclusion 
The previous results suggest the superiority of formula F8 
[microspheres prepared from drug : polymer ratio [1:4], stirring 
rate 800 rpm, and surfactant conc. 0.3%] over the commercially 




[1]. Ward A, Clissold SP. Pentoxifylline. A 
review of its pharmacodynamic and 
pharmacokinetic properties, and its 
therapeutic efficacy. Drugs.;34 (1987) 
50–97.  
[2]. Eun BL, Liu XH, Barks JD. 
Pentoxifylline attenuates hypoxic-
ischemic brain injury in immature rats. 
Pediatr Res;47.(2000)73–78.  
[3]. Muller R. Hemorheology and 
peripheral vascular diseases: A new 
therapeutic approach. J 
Med.;12(1981)209–35. 
[4]. Gunawan I., Achmad S., 
 Moegihardjo,  Soeharyono, Tjiang L., 
Iis W., Lisa A., Harry G. B. 
Pentoxifylline. Analytical Profiles of 
Drug Substances and Excipients 
25(1998)295-339  
[5]. Samlaska CP, Winfield EA. 
Pentoxifylline. J Am Acad 
Dermatol..30(1994)603–21.  
[6]. Hardman J.G., L.E. Limbird, A.G. 
Gilman: The pharmacological basis of 
therapeutics,. 8th ed., Vol. II., New 
York: Maxwell Macmillan Publishing 
Corporation: 1699. (1992) 
[7]. Grigoleith.G., H. Lleonhardit Rheology 
of blood and pentoxifylline, 
Pharmatherapeutica, 1, 10 (1997) 642 
– 651 
[8]. Popovici I., D. Lupuliasa: Tehnologie 
farmaceutică, vol. I, Editura Polirom 
Iaşi: (1997)25 – 37 
[9]. Sudhamani, T., Reddy, K. N., Kumar, 
V. R. R., Revathi, R. and Ganesan, V.: 
preparation and evaluation of ethyl 
cellulose microspheres of ibuprofen 
for sustained drug delivery.  Int. J. 
Pharm. Res. Dev. 2(8) (2010)119-125. 
[10]. Deore, B.V., Mahajan, H. S. and 
Deore U.V.: Development and 
characterization of sustained release 
microspheres by quasi emulsion 
solvent diffusion method. Int. J. 
ChemTech. Res. 1(3): (2009)634-642. 
[11].  Vyas, S. P and Khar, R. K.: Targeted 
and controlled drug delivery- Novel 
carrier systems, 1st edition, CBS 
publishers & distributers, Delhi, (2006) 
414-458. 
[12]. Karal-Yılmaz, O., Serhatl, M., Baysal, 
K. and Baysal, B. M.: Preparation and 
in vitro characterization of vascular 
endothelial growth factor (VEGF)-
loaded poly(D,L-lactic-co-glycolic acid) 
microspheres using a double 
emulsion/solvent evaporation 
technique. J. Microencapsul. 28(1): 
(2011) 46-54. 
[13]. El-Bagory, I. M., Hosny, E. A., Al-
Suwayeh, S. A., Mahrous, G. M. and  
Al-Jenoobi, F. I.: Effects of sphere 
size, polymer to drug ratio and 
plasticizer concentration on the 
release of theophylline from 
ethylcellulose microspheres. Saudi 
Pharm. J. 15(3-4): (2007) 213-217. 
[14]. Liu, H., Pan, W., Ke, P., Dong, Y. and 
Ji, L.: Preparation and evaluation of a 
novel gastric mucoadhesive 
sustained-release acyclovir 
microsphere. Drug. Dev. Ind. Pharm. 
36(9): (2010)1098-1105. 
[15]. Huh, Y., Cho, H. J., Yoon, I. S., Choi, 
M. K. Kim, J. S., Oh, E., Chung, S. J., 
Shim, C. K. and Kim, D. D.: 
Preparation and evaluation of spray-
dried hyaluronic acid microspheres for 
intranasal delivery of fexofenadine  
hydrochloride. Eur. J. Pharm. Sci. 
40(1): (2010)9-15. 
[16]. Rassu, G., Gavini, E., Spada, G., 
Giunchedi, P. and Marceddu, S.  
pentoxiphylline spray-dried 
microspheres based on [AM 
Polymer]RS and RL: study of the 
manufacturing parameters. Drug. Dev. 
Ind. Pharm. 34(11): (2008) 1178-1187. 
[17]. Kibbe, A. H.. Handbook of 
pharmaceutical excipients. 3rd edn. 
Washington, D.C., USA, American 
Pharmaceutical Association, 
(2000)401-406. 
[18]. Apu, A. S., Pathan, A. H., Shrestha, 
D., Kibria, G. and Jalil, J.: 
Investigation of In vitro Release 
Kinetics of Carbamazepine from 
Ammonio Methacrylate Copolymer® 
RS PO and RL PO Matrix Tablets. 
Trop. J. Pharm. Res. 8 (2): (2009) 
145-152. 
[19]. Kawashima Y., Iwamoto T., Niwa T., 
Takeuchi H., Hino T.: J. 
Microencapsul. 10, (1993) 329. 
[20]. Nocent M., Bertochhhi L., Espitalier F., 
Baron B., Couarraze G.: J. Pharm. 
Sci. 90, (2001) 1620. 
[21]. Sato Y., Kawashima Y., Taceuchi H., 
Yamamoto H.: Eur. J. Pharm. 
Biopharm. 20, 1(2003). 
[22]. Devrim B, Canefe K. Preparation and 
evaluation of modified release 
ibuprofen microspheres with acrylic 
polymers (eudragit) by quasi emulsion 
Solvent diffusion method: effect of 
Hosny et al. International Journal of Drug Delivery 3 (4) 734-742 [2011] 
 
PAGE | 739 | 
 
 
variables. Acta Poloniae 
Pharmaceutica & Drug Res.; 
63(2006)521-534. 
[23]. Trivedi, P., Verma, A. M. L. and 
Garud, N.  : Preparation and 
characterization of aceclofenac 
microspheres. Asian J. Pharm. 
(2008)110-115. 
[24]. Ansel, H. C., Popovich, N. G. and 
Allen, J. R.: In Pharmaceutical dosage 
forms and drug delivery systems. 6th 
ed.  Williams and Wilkins. London. 
(1995)P: 175. 
[25]. Behera, B. C., Sao, S. K., Dhal, S., 
Baric, B. B. and Gupta, B. K.: 
Characterization of Glipizide-Loaded 
Polymethacrylate Microspheres 
Prepared By an Emulsion Solvent 
Evaporation Method. Trop. J. Pharm. 
Res. 7 (1): (2008) 879-885. 
[26]. Chinna B, Shyam R., Vimal M., Sleeva 
M., Sai M. Formulation and Evaluation 
of Indomethacin Microspheres using 
natural and synthetic polymers as 
Controlled Release Dosage Forms. 
International Journal of Drug 
Discovery, 2(1), (2010)8-16 
[27]. Anita V., Akanksha T., Shubhini A. , 
Shailendra S. Fabrication and 
evaluation of sustained release 
microsphere of ketorolac 
tromethamine. International Journal of 
Pharmacy and Pharmaceutical 
Sciences. 2(4), 2010 
[28]. Valliappan, K., Kannan, K., 
Sivakumar, T. and Manavalan, R.: 
Enantiospecific pharmacokinetic 
studies on pentoxiphylline in tablet 
formulation using indirect chiral HPLC 
analysis.  J. Appl. Biomed. 4: (2006) 
153–161. 
[29]. Robert V. Smith, Shun K., Patrick 
J. Davis, Michael T. Bauza. 
Determination of pentoxifylline and its 
major metabolites in microbial extracts 
by thin-layer and high-performance 
liquid chromatography. Journal of 
Chromatography (1983)  281-287  
[30]. Meyyanathan, S. N., Muralidharan, S., 
Rajan, S., Gopal, K. and Suresh, B.: A 
Simple Sample Preparation with 
HPLC–UV Method for Estimation of 
Amlodipine from Plasma: Application 
to Bioequivalence Study. The Open 
Chem. Biomed. Meth. J. 1: (2008) 22-
27.    
[31]. Chaisri, C., Hennink, W. E. and 
Okonogi, S.: Preparation and 
characterization of cephalexin loaded 
PLGA microspheres. Cur. Drug Deliv. 
6(2009) 69-75. 
[32]. Parashar, V., Ahmad, D., Gupta, S. P., 
Upmanyu, N., Parashar, N. and 
Mudgal, V.: Formulation and 
evaluation of biodegradable 
microspheres of tinidazole. Int. J. Drug 
Deliv. 2 (2010) 238-241. 
[33]. Mostafa S., Malihe S.,  Mehdi S., 
Formulation and in vitro Evaluation of 
Eudragit L100 Microspheres of 
piroxicam Nature Precedings : 
(2008)27  
[34]. Maia, J. L., Santana, M. H. A. and Re, 
M. I.: The effect of some processing 
conditions on the characteristics of 
biodegradable microspheres obtained 
by an emulsion solvent evaporation 
process. Braz. J. Chem. Eng. 
21(2004) 1-12. 
[35]. Mazumder, B., Dey, S., Bhattacharya, 
S., Sarkar, S. and Mohanta, B.: 
Formulation and cheracterization of 
cellulose-based microspheres of 
chlorpheniramine maleate. Arch. 
Pharm. Sci. 1 (1) (2009) 66-74. 
[36]. Lin, S. Y., Tzan, Y. L., Lee, C. J. and 
Weng, C. N.:  Preparation of enteric-
coated microspheres of mycoplasma 
hypneumoniae vaccine with cellulose 
acetate phethalate (I) formation 
condition and micrometric properties. 
J. Microencapsul. 8(3) (1991) 317-
325. 
[37]. Mao, S., Shi, y., Li, L. Xu, J., Schaper, 
A. and Kissel, T.  : Effect of process 
and formulation parameters on 
characteristics and internal 
morphology of poly (D, L-lactide-co-
glycolide) microspheres formed by the 
solvent evaporation method. Eur. J. 
Pharm. Biopharm. 68 (2008) 214-223. 
[38]. Gupta, B. K., Pal, R., Chakraborty, M. 
and Debnath, R.: Design, evaluation 
and optimization of microcapsules of 
leflunomide with [AM Polymer]RL100 
and [AM Polymer]RS100 by solvent 
evaporation technique. Asian J. 
Pharm. 3 (4) (2009)309-313. 
[39]. Prasanth, V. V,   Chakraborty, A., 
Mathew, S.T., Mathappan, R. and 
Kamalakkannan, V.: Formulation and 
evaluation of Salbutamol sulphate 
microspheres by solvent evaporation 
method. J. of Appl. Pharm. Sci. 1 (5) 
(2011) 133-137. 
[40]. Mateeovic T, Kriznar B, Bogataj M, 
Mrhar A. The influence of stirring rate 
on biopharmaceutical properties of 
Eudragit RS microspheres. J 
Microencapsul. 19 (2005) 29‐36. 
[41]. Pachuau, L. and Mazumder, B.: study 
on the effects of different surfactants 
on Ethylcellulose microspheres. Int. J. 
Pharm. Tech. Res. 1(4) (2009) 966-
971. 
[42]. Cui, F., Yang, M., Jiang, Y., Cun, D., 
Lin, W., Fan, Y. and Kawashima, Y.: 
Design of sustained-release 
nitrendipine microspheres having solid 
dispersion structure by quasi-emulsion 
solvent diffusion method. J. Control. 
Rel. 91(2003)  375–384. 
. 
Hosny et al. International Journal of Drug Delivery 3 (4) 734-742 [2011] 
 



















(%) ± S.D. 
Entrapment 
efficiency (%) ± 
S.D. 
       
F1 1:1 400 0.1% No Microsphere -------- ------- 
F2 1:3 400 0.3% No Microsphere ------- ------- 
F3 1:5 400 0.6% No Microsphere ------- ------- 
F4 1:1 800 0.1% No Microsphere ------- ------- 
F5 1:1 800 0.6% No Microsphere ------- ------- 
F6 1:2 800 0.3% 425±8.34 72.87±3.22 74.65±3.87 
F7 1:3 800 0.3% 453±7.34 84.76±3.23 85.87±5.45 
F8 1:4 800 0.3% 478±6.76 92.87±1.43 91.34±4.54 
F9 1:5 800 0.3% 518±10.3 93.13±2.87 94.22±2.43 
F10 1:2 800 0.6% 364±7.43 74.65±3.76 70.76±2.09 
F11 1:3 800 0.6% 387±9.54 78.54±3.43 80.76±3.65 
F12 1:4 800 0.6% 402±6.98 85.34±1.87 84.96±1.65 
F13 1:5 800 0.6% 423±5.98 90.34±3.43 88.76±2.08 
F14 1:2 1200 0.3% 385±8.45 70.89±2.04 72.34±3.65 
F15 1:3 1200 0.3% 412±9.45 75.45±2.44 83.34±3.85 
F16 1:4 1200 0.3% 432±7.54 85.23±3.09 87.56±3.27 
F17 1:5 1200 0.3% 461±7.95 88.65±3.43 89.58±4.65 
F18 1:2 1200 0.6% 325±6.65 71.34±3.53 68.54±3.86 
F19 1:3 1200 0.6% 339±9.34 77.34±3.23 78.45±1.08 
F20 1:4 1200 0.6% 354±7.56 80.65±4.11 82.65±1.87 
F21 1:5 1200 0.6% 387±6.87 82.45±3.45 86.14±2.98 
 
 
Table (2): Pharmacokinetics parameters of OXP after oral administration of plain OXP, Trental SR, and 
Formula F8. 
 
Pharmacokinetics parameters Formula 
[OXP] Trental SR Formula [F8] 
Cmax (ng/ml) 37.43±2.97 25.43±2.54 22.54±1.43 
Tmax (h) 1.23±0.09 5.32±0.51 7.79±0.24 
Kel (h-1) 0.430±0.12 0.175±0.023 0.113±0.053 
t1/2 (h) 1.61±0.10 3.95±1.21 6.12±0.43 
AUC0-24 (ng.ml-1.h) 660.87±8.64 1420.54±8.65 2340.65±10.43 
AUC0-α (ng.ml-1.h) 720.65±3.12 1580.43±4.65 2470.43±11.43 
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Figure 2: % OXP released from different formulae which fulfilled all the desired criteria required in 
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Figure 3: Mean plasma levels of [OXP] after oral administration of different [OXP] formulations [equivalent 
to 10 mg/ kg] in rabbits. 
 
 
 
 
 
 
 
 
